These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 1400429)

  • 1. Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin.
    Randi AM; Jorieux S; Tuley EA; Mazurier C; Sadler JE
    J Biol Chem; 1992 Oct; 267(29):21187-92. PubMed ID: 1400429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
    Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
    J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.
    Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H
    Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
    Inbal A; Kornbrot N; Harrison P; Randi AM; Sadler JE
    Thromb Haemost; 1993 Dec; 70(6):1058-62. PubMed ID: 8165601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.
    Christophe O; Ribba AS; Baruch D; Obert B; Rouault C; Niinomi K; Piétu G; Meyer D; Girma JP
    Blood; 1994 Jun; 83(12):3553-61. PubMed ID: 8204881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
    Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
    Kroner PA; Kluessendorf ML; Scott JP; Montgomery RR
    Blood; 1992 Apr; 79(8):2048-55. PubMed ID: 1373334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.
    Cooney KA; Nichols WC; Bruck ME; Bahou WF; Shapiro AD; Bowie EJ; Gralnick HR; Ginsburg D
    J Clin Invest; 1991 Apr; 87(4):1227-33. PubMed ID: 1672694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
    Jenkins PV; Pasi KJ; Perkins SJ
    Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
    Matsushita T; Sadler JE
    J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
    Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
    Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
    J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation.
    Ajzenberg N; Ribba AS; Rastegar-Lari G; Meyer D; Baruch D
    Blood; 2000 Jun; 95(12):3796-803. PubMed ID: 10845912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.
    Ribba AS; Christophe O; Derlon A; Cherel G; Siguret V; Lavergne JM; Girma JP; Meyer D; Pietu G
    Blood; 1994 Feb; 83(3):833-41. PubMed ID: 8298143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein.
    Cruz MA; Handin RI; Wise RJ
    J Biol Chem; 1993 Oct; 268(28):21238-45. PubMed ID: 8407961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.